Pharmaceuticals

Nifty Pharma

India is the world's largest producer of generic medicines, supplying 20% of global generics by volume and 60% of global vaccines. The sector operates across three business models: US generics (highly competitive, price-eroding), Indian branded generics (high margins, brand loyalty), and API/CDMO (contract manufacturing for global pharma). The sector is a natural USD earner and benefits from INR depreciation.

Nifty Pharma Close

24,248.05

▲ 0.29%

Index P/E

37.06

Companies

Total Market Cap

₹0

Median P/E

—

Median ROE

—

Median Div Yld

—

Top Company

—

Key Investment Themes

✓US generics stabilising after multi-year price erosion
✓India branded generics growing 8–12% annually — recession-resistant
✓Biosimilars opportunity: India competing in global biologic generics
✓CDMO/API growth as China +1 supply chain diversification
✓Healthcare premiumisation in India driving specialty drug demand

Learn more about valuation →

Key Risks to Watch

⚠USFDA import alerts on Indian manufacturing facilities
⚠Price erosion in US generics from increased competition
⚠API raw material dependence on China (60-70% of key APIs)
⚠Regulatory price controls on essential medicines in India

Top companies in Pharmaceuticals

0 companies

Company master for this sector is still being populated.

P/E, ROE, YoY growth shown when available. YoY growth requires 2+ years of annual financials (top 200 companies refreshed weekly).